KRAS-targeted therapies in advanced solid cancers: drug the undruggable?

被引：5
|
作者：
Saleh, Khalil [1 ]
Kordahi, Manal [2 ]
Felefly, Tony [3 ]
Kourie, Hampig Raphael [4 ]
Khalife, Nadine [5 ]
机构：
[1] Gustave Roussy Canc Campus, Dept Hematol, F-94800 Villejuif, France
[2] Natl Inst Pathol, Dept Pathol, Baabda 1003, Lebanon
[3] St Joseph Univ, Sch Med, Dept Radiat Oncol, Hotel Dieu France Univ Hosp, Beirut 1100, Lebanon
[4] St Joseph Univ, Fac Med, Dept Hematol Oncol, Beirut 1100, Lebanon
[5] Gustave Roussy Canc Campus, Dept Med Oncol, F-94800 Villejuif, France
来源：
PHARMACOGENOMICS | 2021年 / 22卷 / 10期
关键词：
adagrasib; colorectal cancer; KRAS(G12C) mutations; non-small-cell lung cancer; RAS; sotorasib; KRYSTAL-1; ACTIVITY; ADAGRASIB MRTX849; SAFETY;
D O I：
10.2217/pgs-2021-0045
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：587 / 590
页数：4
相关论文
共 50 条
  • [1] Clinical progress of KRAS-targeted therapies: what next?
    Nagasaka, Misako
    Azmi, Asfar S.
    FUTURE MEDICINAL CHEMISTRY, 2022, 14 (15) : 1107 - 1110
  • [2] Combinatorial approaches for mitigating resistance to KRAS-targeted therapies
    Warren, Hannah R.
    Ross, Sarah J.
    Smith, Paul D.
    Coulson, Judy M.
    Prior, Ian A.
    BIOCHEMICAL JOURNAL, 2022, 479 (18) : 1985 - 1997
  • [3] Identification of the mechanisms of resistance to targeted therapies in advanced solid cancers.
    Dease, Olivier
    Dasse, Emilie
    Brulle-Soumare, Laura
    Mevel, Katell
    Bigot, Ludovic
    Loriot, Yohann
    Andre, Fabrice
    Soria, Jean-Charles
    Besse, Benjamin
    Le Ven, Enora
    Cairo, Stefano
    Friboulet, Luc
    Judde, Jean-Gabriel
    CANCER RESEARCH, 2021, 81 (13)
  • [4] The elucidation of drug resistance mechanisms against KRAS-targeted therapy in pancreatic ductal adenocarcinoma
    Takeda, Mitsunobu
    Yao, Wantong
    Draetta, Giulio
    Mori, Ryouta
    Sekido, Yuki
    Hata, Tsuyoshi
    Hamabe, Atsushi
    Ogino, Takayuki
    Miyoshi, Norikatsu
    Uemura, Mamoru
    Doki, Yuichiro
    Eguchi, Hidetoshi
    CANCER SCIENCE, 2024, 115 : 168 - 168
  • [5] Integrated platform enables KRAS-targeted drugs discovery
    Liu, Beibei
    Li, An
    Zuo, Xiangyang
    Yang, Jie
    Wang, Ruifeng
    Fan, Feifei
    Shi, Wenting
    Gu, Qingyang
    CANCER RESEARCH, 2023, 83 (07)
  • [6] KRAS-Targeted Therapy or Angiogenesis: Still a Viable Target?
    Mambetsariev, I.
    Amanam, I.
    Nam, A.
    Salgia, R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1723 - S1724
  • [7] RAS-targeted therapies: is the undruggable drugged?
    Amanda R. Moore
    Scott C. Rosenberg
    Frank McCormick
    Shiva Malek
    Nature Reviews Drug Discovery, 2020, 19 : 533 - 552
  • [8] Intercepting pancreatic cancer development with mutant KRAS-targeted immunotherapy
    Zaidi, Neeha
    Huff, Amanda
    Marcisak-Davis, Emily
    Haldar, Daniel
    Heumann, Thatcher
    Konig, Max
    Mog, Brian
    Montagne, Janelle
    Longway, Gabriella
    Andaloori, Lalitya
    Lyman, Melissa
    Danilova, Ludmila
    Nauroth, Julie
    Kagohara, Luciane
    Fertig, Elana
    Azad, Nilo
    Jaffee, Elizabeth
    CANCER RESEARCH, 2022, 82 (22)
  • [9] Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers
    He, Hao
    Xu, Chang
    Cheng, Zhao
    Qian, Xiaoying
    Zheng, Lei
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2019, 19 (23) : 2128 - 2142
  • [10] RAS-targeted therapies: is the undruggable drugged?
    Moore, Amanda R.
    Rosenberg, Scott C.
    McCormick, Frank
    Malek, Shiva
    NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (08) : 533 - 552
12345